Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...

Scientists have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that has long been limited by the protective nature ...

Cronometer, a leader in nutrition and health tracking, is proud to announce the integration of Continuous Glucose Monitors (CGMs) with its innovative platform. This feature provides users with the ...

Scientists have developed a lipid nanoparticle system that enables mRNA to cross the blood-brain barrier, a long-standing challenge in n.

Several large Massachusetts employers have filed annual reports with federal securities regulators that are notable for ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

It was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc. GILD gained following the earnings beat and upbeat guidance for 2025, ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...